Development of a Novel Nanoparticle-based Therapeutic Vaccine for Breast Cancer Immunotherapy

Procedia in vaccinology Pub Date : 2014-01-01 DOI:10.1016/j.provac.2014.07.011

Eva Zupančič , JoanaM Silva , Mafalda A. Videira , João N. Moreira , Helena F. Florindo

{"title":"Development of a Novel Nanoparticle-based Therapeutic Vaccine for Breast Cancer Immunotherapy","authors":"Eva Zupančič , JoanaM Silva , Mafalda A. Videira , João N. Moreira , Helena F. Florindo","doi":"10.1016/j.provac.2014.07.011","DOIUrl":null,"url":null,"abstract":"<div><p>Nanoparticles (NPs) have great potential as advanced delivery systems for cancer immunotherapy. PEGylated-Poly- lactide-co-glycolic acid-based (PLGA-PEG) NPs were prepared by double-emulsion solvent evaporation technique, using ovalbumin (OVA) as a model antigen. Glycol Chitosan and block co-polymer Pluronic F127 were used in order to best attain the most efficient parameters for cancer immunotherapy. OVA-loaded PLGA-PEG NPs presented a narrow size distribution with an average size of 167nm witha polidisperity index (PdI)0.167 and zeta potential values close to neutrality (-1.66mV), which is desired for a particulate cancer vaccine to overcome their premature capture by macrophages. The encapsulation efficiency (EE) and loading capacity (LC) of these NPs were 57.5% and 29μg/mg, respectively. PLGA-PEG NPs modified with Pluronic F127 presented slightly higher Z- Average (180nm with a PdI 0.18), and ZP (ZP -1.78mV), but lower EE and LC (32% and 16μg/mg). The effect of NPs on dendritic cell viabilitywas evaluated using Alamar Blue® assays.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"8 ","pages":"Pages 62-67"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.011","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Procedia in vaccinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877282X14000125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

Nanoparticles (NPs) have great potential as advanced delivery systems for cancer immunotherapy. PEGylated-Poly- lactide-co-glycolic acid-based (PLGA-PEG) NPs were prepared by double-emulsion solvent evaporation technique, using ovalbumin (OVA) as a model antigen. Glycol Chitosan and block co-polymer Pluronic F127 were used in order to best attain the most efficient parameters for cancer immunotherapy. OVA-loaded PLGA-PEG NPs presented a narrow size distribution with an average size of 167 nm witha polidisperity index (PdI)0.167 and zeta potential values close to neutrality (-1.66 mV), which is desired for a particulate cancer vaccine to overcome their premature capture by macrophages. The encapsulation efficiency (EE) and loading capacity (LC) of these NPs were 57.5% and 29 μg/mg, respectively. PLGA-PEG NPs modified with Pluronic F127 presented slightly higher Z- Average (180 nm with a PdI 0.18), and ZP (ZP -1.78 mV), but lower EE and LC (32% and 16 μg/mg). The effect of NPs on dendritic cell viabilitywas evaluated using Alamar Blue® assays.

查看原文本刊更多论文

一种新型纳米颗粒乳腺癌免疫治疗疫苗的研制

纳米粒子(NPs)作为癌症免疫治疗的先进递送系统具有巨大的潜力。以卵清蛋白(OVA)为模型抗原，采用双乳溶剂蒸发技术制备聚乳酸-聚乙二醇基(PLGA-PEG) NPs。乙二醇壳聚糖和嵌段共聚物Pluronic F127被用于肿瘤免疫治疗。ova负载的PLGA-PEG NPs的尺寸分布较窄，平均尺寸为167 nm，多态指数(PdI)为0.167,zeta电位值接近中性(-1.66 mV)，这是颗粒癌疫苗克服其被巨噬细胞过早捕获的必要条件。其包封率为57.5%，载药量为29 μg/mg。Pluronic F127修饰的PLGA-PEG NPs具有较高的Z- Average (180 nm, PdI 0.18)和ZP (ZP -1.78 mV)，较低的EE和LC (32%， 16 μg/mg)。NPs对树突状细胞活力的影响采用Alamar Blue®检测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Procedia in vaccinology

自引率

0.00%

发文量